醋酸亮丙瑞林联合生长激素治疗中枢性性早熟女孩的有效性和安全性

储微; 张偲; 沈玉霞; 罗小平

doi:10.13407/j.cnki.jpp.1672-108X.2020.09.004

您当前的位置：

首页 >

文章列表页 >

醋酸亮丙瑞林联合生长激素治疗中枢性性早熟女孩的有效性和安全性

论著（儿科药物治疗学） | 更新时间：2022-11-03

- 醋酸亮丙瑞林联合生长激素治疗中枢性性早熟女孩的有效性和安全性
- Efficacy and Safety of Leuprolide Acetate Combined with Growth Hormone in the Treatment of Girls with Central Precocious Puberty
- 儿科药学杂志 2020年26卷第9期页码：12-15
- 作者机构：
  
  1. 华中科技大学同济医学院附属同济医院,湖北,武汉,430030
  2. 安徽中医药临床研究中心附属医院,安徽,合肥,230000
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.09.004
  中图分类号：
- 纸质出版日期：2020，
  
  网络出版日期：2020-9-10，
扫描看全文
储微, 张偲, 沈玉霞, 等. 醋酸亮丙瑞林联合生长激素治疗中枢性性早熟女孩的有效性和安全性[J]. 儿科药学杂志, 2020,26(9):12-15.

Chu Wei, Zhang Cai, Shen Yuxia, et al. Efficacy and Safety of Leuprolide Acetate Combined with Growth Hormone in the Treatment of Girls with Central Precocious Puberty[J]. 2020,26(9):12-15.
储微, 张偲, 沈玉霞, 等. 醋酸亮丙瑞林联合生长激素治疗中枢性性早熟女孩的有效性和安全性[J]. 儿科药学杂志, 2020,26(9):12-15. DOI： 10.13407/j.cnki.jpp.1672-108X.2020.09.004.

Chu Wei, Zhang Cai, Shen Yuxia, et al. Efficacy and Safety of Leuprolide Acetate Combined with Growth Hormone in the Treatment of Girls with Central Precocious Puberty[J]. 2020,26(9):12-15. DOI： 10.13407/j.cnki.jpp.1672-108X.2020.09.004.

摘要

目的：探讨中枢性性早熟（CPP）女孩安全、有效的治疗方法。方法：选择2013年10月至2017年10月同济医院收治的CPP女孩34例，按照随机对照方法分为研究组19例和对照组15例。研究组使用醋酸亮丙瑞林+生长激素治疗，对照组使用醋酸亮丙瑞林治疗，比较两组患儿治疗24个月后黄体生成素（LH）峰值和LH峰值/卵泡刺激素（FSH）峰值抑制至青春期前水平的受试者比例，预测成人身高（PAH）较基线有改善的受试者比例以及改善情况，比较两组患儿治疗前后空腹血糖（FPG）、胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）水平以及不良反应发生情况。结果：治疗24个月后，对照组和研究组LH峰值受到抑制的受试者比例均为100%，LH峰值/FSH峰值受到抑制的受试者比例分别为100%、94.74%；PAH与基线相比有改善的受试者比例均为100%，PAH从治疗前到24个月后的平均值（SD）变化分别为（14.00±0.79）cm、（17.00±1.12）cm。治疗前后两组患儿FPG、TC、TG、HDL-C、LDL-C比较差异均无统计学意义（P均>0.05）。两组分别报告了4例和5例不良反应，均为轻中度。结论：两组CPP女孩接受治疗后，PAH均明显高于基线时的PAH，研究组PAH较对照组略有升高，但是差异无统计学意义。两组不良反应发生率均较低，均为轻中度。

Abstract

Objective: To probe into the safe and effective treatment methods for girls with central precocious puberty (CPP). Methods: Totally 34 girls with CPP admitted into Tongji Hospital from Oct. 2013 to Oct. 2017 were extracted to be divided into the study group and the control group via the random number table

with 19 cases in each group. The study group was treated with leuprolide acetate + growth hormone

and the control group received leuprolide acetate. Proportion of subjects with peak luteinizing hormone (LH) suppression

and peak LH/peak follicle stimulating hormone (FSH) suppression to prepubertal levels

proportion of subjects with an improvement in predicted adult height (PAH) from baseline of two groups were compared after treatment of 24 months. Fasting blood glucose (FPG)

cholesterol (TC)

triglycerides (TG)

high density lipoprotein cholesterol (HDL-C)

low density lipoprotein cholesterol (LDL-C) levels and the incidence of of adverse drug reactions of two groups were observed. Results: After treatment of 24 months

the proportions of subjects with peak LH suppression in two groups were 100%. The proportions of subjects with peak LH/peak FSH suppression to prepubertal levels in the control group and the study group were respectively 100% and 94.74%. The proportion of subjects with improvement of PAH compared with baseline was 100%. The mean (SD) changes of PAH from before treatment to 24 months after treatment were (14.00±0.79) cm and (17.00±1.12) cm

respectively. There was no significant difference in FPG

HDL-C and LDL-C between two groups before and after treatment (P>0.05). Adverse drug reactions were reported in 4 and 5 cases in two groups

which were mild and moderate. Conclusion: After treatment for two group of girls with CPP

the PAH was significantly higher than that of the baseline. The PAH of the study group was slightly higher than that of the control group

yet the difference was not statistically significant. The incidence of adverse drug reactions in both groups was relatively low

all of which were mild and moderate.

关键词

醋酸亮丙瑞林生长激素预测成人身高中枢性性早熟

Keywords

leuprorelin acetategrowth hormonepredicted adult heightcentral precocious puberty

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

药事干预在儿童生长激素使用管理中的作用

重组人生长激素联合亮丙瑞林治疗特发性中枢性性早熟女童的疗效

来曲唑辅助治疗生长激素缺乏型矮小症男童的临床价值